Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 14/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.42 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.40 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3738813 | 0.93 | NAMPT (0.46) | NAMPTPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3734785 | 0.91 | NAMPT (0.47) | NAMPTPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3731650 | 0.91 | NAMPT (0.52) | NAMPTPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3733390 | 0.90 | NAMPT (0.49) | NAMPTCYP2C9PIK3CAPIK3CDPIK3CB | |
| SCHEMBL3731787 | 0.87 | NAMPT (0.45) | NAMPTPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3731366 | 0.86 | NAMPT (0.48) | NAMPTPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3734293 | 0.84 | NAMPT (0.45) | NAMPTPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3733687 | 0.84 | NAMPT (0.49) | NAMPTICAM1MCHR1 | |
| SCHEMBL3741303 | 0.84 | NAMPT (0.47) | NAMPTPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3734029 | 0.84 | NAMPT (0.47) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825120-B2 | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas | CYTOKINETICS, INC. (US) | 2010-11-02 | — | — | US | claimed |
| EP-1959963-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2008-08-27 | — | — | EP | claimed |
| US-20070197504-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-08-23 | — | — | US | claimed |
| WO-2007089336-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-08-09 | — | — | WO | claimed |
| US-7825120-B2 | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas | CYTOKINETICS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| EP-1959963-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20070197504-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007089336-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197504-A1 | Certain chemical entities, compositions and methods | TNNI3, TNNT2, MYLK2 | NAMPT 3645/4885CYP2C9 4516/4885PIK3CA 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.